Research programme: allergic asthma therapy - CJ CorporationAlternative Names: E-CpG ODN
Latest Information Update: 29 Aug 2007
At a glance
- Originator CJ Corporation
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 29 Aug 2007 Discontinued - Preclinical for Allergic asthma in South Korea (unspecified route)
- 20 Apr 2005 Preclinical trials in Allergic asthma in South Korea (unspecified route)